Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines ...

Patients with moderate to severe allergic rhinitis (AR) often experience years of uncontrolled symptoms, worsened quality of ...

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug ...

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Cardiovascular risk factor control in Mexican adults with diabetes is suboptimal, with low rates of glycemic, blood pressure, ...